risperidone has been researched along with Parkinson Disease in 37 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot study investigated effectiveness and tolerability of risperidone for the treatment of psychosis and agitation in 9 inpatients with Parkinson's disease and dementia." | 5.08 | The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. ( Bakey, AA; Kunik, ME; Molinari, VA; Orengo, CA; Workman, RH, 1997) |
| "Risperidone, a novel neuroleptic with approximately equal D2 and 5HT2A receptor blocking properties, has been used to treat drug-related hallucinations in patients with Parkinson's disease." | 3.70 | Risperidone treatment of drug-related psychosis in patients with parkinsonism. ( Leopold, NA, 2000) |
| "We present a case in which the use of low dose risperidone (a potent D2 and 5-HT2 antagonist) was successful in controlling gambling behaviour secondary to dopamine agonist treatment of Parkinson's disease." | 3.70 | Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. ( Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ, 2000) |
| "Although the mean motor Unified Parkinson's Disease Rating Scale score worsened in the risperidone group and improved in the clozapine group, this difference did not reach statistical significance." | 2.69 | Clozapine and risperidone treatment of psychosis in Parkinson's disease. ( Cudkowicz, ME; Ellis, T; Growdon, JH; Sexton, PM, 2000) |
| "Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS)." | 2.69 | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. ( De Deyn, PP; Hildebrand, K; Mendis, T; Mohr, E, 2000) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "2." | 2.39 | Psychosis in Parkinson's disease: diagnosis and treatment. ( Deveaugh-Geiss, J; Doraiswamy, M; Martin, W; Metz, A, 1995) |
| "Though it was difficult to control their visual hallucinations with medication only, cataract surgery made them disappeared quickly." | 1.32 | [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery]. ( Kameyama, M; Kubori, T; Matsui, H; Nishinaka, K; Oda, M; Udaka, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (37.84) | 18.2507 |
| 2000's | 18 (48.65) | 29.6817 |
| 2010's | 4 (10.81) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Lilja, S | 1 |
| Tolppanen, AM | 1 |
| Koponen, M | 1 |
| Hartikainen, S | 1 |
| Tiihonen, M | 1 |
| Wilby, KJ | 1 |
| Johnson, EG | 1 |
| Johnson, HE | 1 |
| Ensom, MHH | 1 |
| Iketani, R | 1 |
| Imai, S | 1 |
| Horiguchi, H | 1 |
| Furushima, D | 1 |
| Fushimi, K | 1 |
| Yamada, H | 1 |
| Chen, CK | 1 |
| Wu, JH | 1 |
| Palminteri, S | 1 |
| Lebreton, M | 1 |
| Worbe, Y | 1 |
| Grabli, D | 1 |
| Hartmann, A | 1 |
| Pessiglione, M | 1 |
| Friedman, JH | 6 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Fernandez, HH | 1 |
| Theodoulou, G | 1 |
| Milner, G | 1 |
| Jumaian, A | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Matsui, H | 1 |
| Udaka, F | 1 |
| Oda, M | 1 |
| Kubori, T | 1 |
| Nishinaka, K | 1 |
| Kameyama, M | 1 |
| Baskys, A | 1 |
| Katz, IR | 1 |
| Stein, DJ | 2 |
| Grant, JE | 1 |
| Honer, WG | 1 |
| Kopala, LC | 1 |
| Rabinowitz, J | 1 |
| Rustembegovic, A | 1 |
| Sofic, E | 1 |
| Wichart, I | 1 |
| Chou, KL | 1 |
| Borek, LL | 1 |
| Meco, G | 2 |
| Alessandria, A | 1 |
| Bonifati, V | 2 |
| Giustini, P | 2 |
| Ford, B | 1 |
| Lynch, T | 1 |
| Greene, P | 1 |
| Tavares, AR | 1 |
| McKeith, IG | 1 |
| Ballard, CG | 1 |
| Harrison, RW | 1 |
| Beck, BJ | 1 |
| Stip, E | 1 |
| Tourjman, V | 1 |
| Lew, V | 1 |
| Fabian, J | 1 |
| Cormier, H | 1 |
| Landry, P | 1 |
| Lalonde, P | 1 |
| Cournoyer, J | 1 |
| Rich, SS | 1 |
| Ott, BR | 2 |
| Doraiswamy, M | 1 |
| Martin, W | 1 |
| Metz, A | 1 |
| Deveaugh-Geiss, J | 1 |
| Damecour, CL | 1 |
| Turcotte, JR | 1 |
| Alessandri, A | 1 |
| Workman, RH | 1 |
| Orengo, CA | 1 |
| Bakey, AA | 1 |
| Molinari, VA | 1 |
| Kunik, ME | 1 |
| Shiwach, RS | 1 |
| Woods, S | 1 |
| Geizer, M | 1 |
| Ancill, RJ | 1 |
| Leopold, NA | 1 |
| Seedat, S | 1 |
| Kesler, S | 1 |
| Niehaus, DJ | 1 |
| Ellis, T | 1 |
| Cudkowicz, ME | 1 |
| Sexton, PM | 1 |
| Growdon, JH | 1 |
| Mohr, E | 1 |
| Mendis, T | 1 |
| Hildebrand, K | 1 |
| De Deyn, PP | 1 |
| Factor, SA | 1 |
| Molho, ES | 1 |
| Stryjer, R | 1 |
| Bar, F | 1 |
| Strous, RD | 1 |
| Baruch, Y | 1 |
| Rabey, JM | 1 |
9 reviews available for risperidone and Parkinson Disease
| Article | Year |
|---|---|
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parki | 2017 |
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled | 2004 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkins | 2007 |
Neuropsychiatric manifestations of diffuse Lewy body disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Brain Stem; Clozapine; Dopamine Antagonists; Humans; Lewy B | 1995 |
Psychosis in Parkinson's disease: diagnosis and treatment.
Topics: Clozapine; Diagnosis, Differential; Humans; Parkinson Disease; Psychotic Disorders; Risperidone | 1995 |
5 trials available for risperidone and Parkinson Disease
| Article | Year |
|---|---|
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli | 2005 |
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.
Topics: Aged; Antipsychotic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; | 1997 |
The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Dementia; Female; Humans; Male; Parkinson Disease; Pilot Projects; Psych | 1997 |
Clozapine and risperidone treatment of psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Blind Method; Humans; | 2000 |
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Belgium; Canada; Dopamin | 2000 |
23 other studies available for risperidone and Parkinson Disease
| Article | Year |
|---|---|
Incidence of antipsychotic use among community dwellers with and without Parkinson's disease.
Topics: Antipsychotic Agents; Cohort Studies; Humans; Incidence; Parkinson Disease; Quetiapine Fumarate; Ris | 2022 |
Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson's disease: a retrospective cohort study using administrative claims data.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Male; Parkinson | 2019 |
Improvement of risperidone-related tardive parkinsonism with a switch to aripiprazole.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Parkinson | 2009 |
Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes.
Topics: Adolescent; Adult; Avoidance Learning; Conditioning, Psychological; Cues; Dopamine Agonists; Dopamin | 2009 |
Recommendations on the drug treatment of psychosis in Parkinson's disease.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Parkinson Disease; Psychotic Disorders; Quetiapine | 2010 |
Neuroleptics and family history of Parkinson diseases: case report.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Diagnostic Errors; Female; | 2001 |
[Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cataract Extraction; Female; Hallucinations; Humans; Levo | 2004 |
Betting on dopamine.
Topics: Antipsychotic Agents; Brain; Diagnostic and Statistical Manual of Mental Disorders; Disruptive, Impu | 2005 |
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Hu | 2006 |
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antipsychotic Agents; Hallucinations; Humans; Isoxazoles; Levodopa; Parkinson Disease; Piperid | 1994 |
Risperidone in Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Parkinson Disease; Piperidines; Psychotic Disorders; Rispe | 1994 |
Risperidone in Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Parkinson Disease; Piperidines; Risperidone | 1995 |
Neuroleptic sensitivity to risperidone in Lewy body dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Iso | 1995 |
"Awakenings" effect with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Humans; Parkinson Disease; Psychotic Disorders; | 1995 |
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
Topics: Aged; Antiparkinson Agents; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Parkinson Disease; Pa | 1995 |
Therapeutic dilemma: psychosis and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lev | 1995 |
Risperidol and withdrawal bruxism in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Bruxism; Delusions; Dopamine Antagonists; Humans; Male; Parkinson Diseas | 1998 |
Combination of risperidone and donepezil in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combinatio | 1998 |
Should risperidone be used in Parkinson's disease?
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Risperidone | 1998 |
Risperidone treatment of drug-related psychosis in patients with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Female; Hallucinations; Humans; | 2000 |
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Hum | 2000 |
Risperidone and Parkinson's disease.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; Risperidone | 2002 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |